Johnson & Johnson (NYSE:JNJ) Shares Sold by D L Carlson Investment Group Inc.

D L Carlson Investment Group Inc. lessened its stake in Johnson & Johnson (NYSE:JNJ) by 0.2% in the fourth quarter, Holdings Channel reports. The fund owned 34,945 shares of the company’s stock after selling 86 shares during the quarter. Johnson & Johnson makes up about 0.9% of D L Carlson Investment Group Inc.’s holdings, making the stock its 27th biggest holding. D L Carlson Investment Group Inc.’s holdings in Johnson & Johnson were worth $5,054,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in JNJ. AIA Group Ltd grew its holdings in Johnson & Johnson by 67.9% during the 4th quarter. AIA Group Ltd now owns 48,252 shares of the company’s stock valued at $6,978,000 after purchasing an additional 19,509 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Johnson & Johnson by 1.8% in the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company’s stock worth $3,522,447,000 after acquiring an additional 431,205 shares in the last quarter. Partners in Financial Planning purchased a new position in Johnson & Johnson in the fourth quarter valued at about $407,000. Everstar Asset Management LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $428,000. Finally, Delos Wealth Advisors LLC raised its position in shares of Johnson & Johnson by 3.3% in the 4th quarter. Delos Wealth Advisors LLC now owns 2,530 shares of the company’s stock valued at $366,000 after purchasing an additional 80 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.3 %

Shares of JNJ stock opened at $163.63 on Monday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm has a market capitalization of $394.32 billion, a PE ratio of 24.61, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The stock has a fifty day moving average of $158.68 and a two-hundred day moving average of $156.07. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the prior year, the firm posted $2.29 EPS. Johnson & Johnson’s revenue was up 5.3% compared to the same quarter last year. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.03%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on JNJ shares. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Wells Fargo & Company cut their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Barclays boosted their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 19th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Insider Activity

In related news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.